Can a diabetes kidney drug protect the kidneys in everyday care?
NCT ID NCT07841015
First seen Sep 25, 2026 · Last updated Sep 25, 2026
Summary
Researchers are observing how finerenone affects the urinary albumin-to-creatinine ratio, a marker of kidney health, in adults with type 2 diabetes and chronic kidney disease. The study enrolls about 800 people receiving care at primary care clinics in Mexico. Participants receive finerenone only if their own doctor prescribes it as part of routine care, and researchers track their kidney measurements, lab results, and side effects for up to 12 months. The goal is to understand how the drug is used and how people respond in real-world primary care settings.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- finerenone, a drug prescribed for kidney and heart protection in people with type 2 diabetes and chronic kidney disease
- What this could lead to
- If finerenone lowers the urine protein marker in routine primary care, it could support broader use of the drug to slow kidney damage in people with type 2 diabetes and chronic kidney disease.
- What could go wrong
- This observational study does not assign treatment, so it cannot prove finerenone causes any change in kidney markers. Results may reflect differences in who receives the drug and how closely they are followed rather than the drug itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 800 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients aged ≥18 years with T2D and CKD, of both sexes, treated in IMSS primary care units, who start treatment with finerenone as part of routine clinical practice.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult participant - all genders (\>=18 years old). * Documented diagnosis of Type 2 diabetes (T2D), according to clinical criteria used in routine clinical practice. * Documented diagnosis of Chronic Kidney Disease (CKD) in stages G2 to G3b, defined by an estimated glomerular filtration rate (Estimated Glomerular Filtration Rate \[eGFR\] \>=30 and \<90 mL/min/1.73 m\^2 according to the information available in the clinical record). * Baseline urinary albumin-to-creatinine ratio (uACR) value \>=30 mg/g, documented at the time of inclusion in the study. * Decision to initiate treatment with finerenone made by the physician as part of his or her routine clinical practice and independently of the patient's inclusion in the study. * Baseline serum potassium \<5.0 mmol/L, determined prior to or at the time of inclusion in the study. * Signed informed consent. * Prescription of finerenone within the authorized indications and in accordance with the prescribing information in force in the local market. * No contraindications to the use of finerenone, in accordance with local marketing authorization and prescribing information in force. Exclusion Criteria: * Concomitant participation in an interventional clinical study involving interventions outside of routine clinical practice at any time during the follow-up period of the present study. * Contra-indications according to the local label.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney disease (CKD) stages G2 TO G3B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Many locations
Multiple Locations, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new pill aims at weight and blood sugar
- Diabetes nerve damage may disrupt the Brain's blood supply
- Can a portable ultrasound scan replace costly scans for muscle loss?
- Can a glucose sensor and daily texts tame diabetes distress?
- Can mindfulness and yoga rewire diabetes habits?
- Can a vegan diet delivered online help people with type 2 diabetes?